NCT00773838 · MORE INFO

Limitations, agreements, and source contact

Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) · Source last updated 2021-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The Sponsor have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialsDisclosure@merck.com
organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
title: Senior Vice President, Global Clinical Development

Complete source fields

certain Agreement

other Details: The Sponsor have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: ClinicalTrialsDisclosure@merck.com
organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
title: Senior Vice President, Global Clinical Development

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice